Corcept Therapeutics (CORT) Climbs 26.6% on Stellar Clinical Trial Result

We recently published 10 Stocks With Effortless Double-, Triple-Digit Gains. Corcept Therapeutics Inc. (NASDAQ:CORT) was one of the top performers last week.

Corcept Therapeutics saw its share prices jump by 26.6 percent week-on-week, as investors took heart from the strong clinical trial results of its drug candidate, relacorilant, in patients with platinum-resistant ovarian cancer.

In an updated report, Corcept Therapeutics Inc. (NASDAQ:CORT) said that relacorilant, when combined with nab-paclitaxel chemotherapy, showed a 35 percent reduction in death risks in patients, as compared with those treated with nab-paclitaxel alone, during the third phase of its clinical trial. The therapy was able to cut disease progression by 30 percent.

The median overall survival for patients receiving relacorilant was 16 months, as compared with 11.9 months for those receiving nab-paclitaxel alone.

Corcept Therapeutics Inc. (NASDAQ:CORT) said that relacorilant, in combination with nab-paclitaxel, was well-tolerated, consistent with its known safety profile.

The trial enrolled a total of 381 patients with platinum-resistant ovarian cancer at sites in the United States, Europe, South Korea, Brazil, Argentina, Canada, and Australia. Patients were randomized 1:1 to receive either relacorilant plus nab-paclitaxel or nab-paclitaxel alone.

Corcept Therapeutics Inc. (NASDAQ:CORT) said that complete results from the study are set to be announced at an upcoming medical conference.

While we acknowledge the potential of CORT as an investment, our conviction lies in the belief that some AI stocks hold greater promise for delivering higher returns and have limited downside risk. If you are looking for an extremely cheap AI stock that is also a major beneficiary of Trump tariffs and onshoring, see our free report on the best short-term AI stock.

READ NEXT: 30 Stocks That Should Double in 3 Years and 11 Hidden AI Stocks to Buy Right Now.

Disclosure: None. This article is originally published at Insider Monkey.